Navigation Links
FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Date:9/17/2007

Lower Strength of Approved Constipation Drug Offers Potential Treatment

Option to Americans Suffering from IBS-C

BETHESDA, Md., Sept. 17 /PRNewswire-FirstCall/ -- Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP) today announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA). Sucampo Pharmaceuticals currently anticipates a decision from the FDA in the second quarter of 2008.

Lubiprostone, a chloride channel activator with a novel mechanism of action, was developed by Sucampo Pharmaceuticals. The 24-mcg formulation of the drug (AMITIZA(R)) is approved for the treatment of Chronic Idiopathic Constipation in adults and is marketed for this indication in the United States by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America, Inc.

"The FDA's decision to accept our sNDA submission for review is an important step in filling an unmet medical need for patients with the debilitating disease of IBS-C," said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer of Sucampo Pharmaceuticals. "IBS-C has a significant impact on millions of Americans and, if approved, lubiprostone may offer a valuable new treatment option for people living with this condition."

Approximately 58 million Americans have irritable bowel syndrome (IBS), with IBS-C accounting for approximately one-third of these cases. IBS-C symptoms include abdominal pain and discomfort associated with defecation or a change in bowel habits with features of disordered defecation.

About l
'/>"/>

SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. UWM accepts resignation of research dean
2. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
3. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
4. Quintessence cancer treatment chosen for clinical studies
5. ZyStor to exhibit cell disorder treatments
6. Radiology advance points way to non-invasive brain-cancer treatment
7. Animal testing: Beyond the protests, instances of mistreatment are rare
8. TomoTherapy leads the industry in CT image-guided treatments
9. Medical College getting $18.1 million to study radiation damage treatments
10. `Single-sales factor extends tax treatment to tech, service firms
11. Research on fruit flies opens up possibilities for human treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... a "biotech hotspot," this time in e-mail newsletter FierceBiotech. ... profile and is just what the biotech industry has ... of five hotspots were California, Maryland, New Jersey and ... list, told Forbes it was a subjective ranking based ...
... qualified for investor tax credits under Wisconsin's Act 255. That ... companies so far have come from. Wisconsin gives the tax ... , StrandVision , in Eau Claire, makes digital signs ... Systems & Services Inc. , in Sheboygan, provides engineering, production ...
... has posted a $21 million bond to pay damages and ... in a patent case, pending appeal. , ,Third Wave and ... has the right to commercialize certain molecular diagnostics methods. A ... later awarded them tripled damages of $15.9 million. , ,Stratagene ...
Cached Biology Technology:
(Date:5/17/2013)... the science and technology of the region and ... inaugural Atlanta Science Festival, March 22-29, 2014. With ... K-12 schools and universities, the festival will host ... adults at venues across the city. Learn more ... Atlanta Science Festival is a collaboration of scientific, ...
(Date:5/17/2013)... Dartmouth College study finds human-caused climate change may ... lizards, contradicting a host of recent studies that ... planet. , The findings, which appear in the ... hope for survival of a creature thought to ... that tropical cold-blooded animals, especially forest lizards, will ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Endocrine Society (ENDO) 95th Annual Meeting ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the ENDO 2013 Annual Meeting. , Awards ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Climate change may have little impact on tropical lizards 2
... This release is available in Spanish . ... , Spain, have generated artificial human skin by tissular engineering ... mice, and optimal development, maturation and functionality results were obtained. ... skin and its use in many laboratory tests on biological ...
... Duke University Medical Center and Laboratory Corporation of ... formation of a joint venture to commercialize new ... the translation of newly discovered biomarkers into widely ... responses, predict disease progression, and evaluate any number ...
... CA April 19, 2010 Scientists from The Scripps ... of how certain genetic mutations lead to Type 1 diabetes. ... Type 1 diabetes and other autoimmune diseases. The study ... Journal of Clinical Investigation on April 19, 2010, and ...
Cached Biology News:Scientists create artificial human skin with biomechanical properties using tissue engineering 2Duke, LabCorp combine forces to create the Biomarker Factory 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 3
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
... an anodized aluminum, solvent-resistant block specially designed ... efficient thermal transfer to samples within the ... HT96 Isothermal Block replaces Cat. No. 71031-3, ... for compatibility with robotic applications. The new ...
Biology Products: